Thermo Fisher Scientific Inc (TMO)
580.15
-4.00
(-0.68%)
USD |
NYSE |
Mar 18, 16:00
581.00
+0.85
(+0.15%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 221.22B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 7.93% |
Valuation | |
PE Ratio | 37.55 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 5.252 |
Price to Book Value | 4.733 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.39 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.7471 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 35.07% |
Profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
URL | https://www.thermofisher.com |
Investor Relations URL | https://ir.thermofisher.com |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Large Cap/Blend |
Next Earnings Release | Apr. 26, 2024 (est.) |
Last Earnings Release | Jan. 31, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 14, 2024 |
Ratings
Profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
URL | https://www.thermofisher.com |
Investor Relations URL | https://ir.thermofisher.com |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Large Cap/Blend |
Next Earnings Release | Apr. 26, 2024 (est.) |
Last Earnings Release | Jan. 31, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 14, 2024 |